The clinical and pathological features of 35 cases with multiple system atrophy collected in the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) between 1985 and 1992 have been analysed. The median age of onset was 55 (range 33.3-75-8) years and median survival was 7-3 (range 2-1-11.5) years. Parkinsonism, usually asymmetric, occurred in all, and autonomic failure in all but one case. Cerebellar signs were noted in 34% and pyramidal features in 54% of the cases.
Multiple system atrophy is a sporadic degenerative disease of the nervous system that causes any combination of parkinsonism, autonomic and cerebellar dysfunction, and pyramidal signs.'-3 Pathologically, it is characterised by varying degrees of cell loss and gliosis principally affecting the substantia nigra and putamen (striatonigral degeneration), pontine nuclei, cerebellar (9 5%) showed the pathological changes of multiple system atrophy and form the basis of this paper. Thirteen of these patients, all with a clinical diagnosis of multiple system atrophy, had been seen in life by one of us (NPQ). The remaining 22 had been followed up by other physicians, 17 of whom were neurologists. Clinicopathological details of nine and an assessment of levodopa response in 21 of these cases have previously been reported.67 CLINICAL DATA The clinical features of the 35 cases were abstracted from clinical records by GKW and entered on a database for subsequent analysis. If no mention of a clinical feature could be found in the notes, then the feature was coded as absent. In some cases, a patient may have had such a feature but this was either not evaluated or recorded. Hence the proportions of patients with the presence of a feature should be treated as a "conservative" estimate.
Autonomic failure was defined as the presence of any of the following: symptomatic postural hypotension, urinary urge incontinence, faecal incontinence, urinary retention requiring catheterisation, or persistent erectile failure. Severe autonomic failure, for men, was defined as two or more of the following five symptoms: syncope, urinary incontinence, faecal incontinence, urinary retention, and erectile failure. For women, the definition of severe autonomic failure was based on two or more of the symptoms, excluding erectile failure.
Akinesia (usually with rigidity) was necessary for a diagnosis of parkinsonism. The average degree of cell loss and gliosis in the affected parts (severity) was semiquantitatively rated by one of the authors (SED), without knowledge of clinical features, on a 4 point scale ranging from normal (0) to severe (3) in the following sites: putamen, caudate nucleus, globus pallidus, substantia nigra, locus ceruleus, pontine nuclei, inferior olives, and cerebellar Purkinje cells. In addition to the degree of cell loss (severity), the area of putaminal damage was assessed by dividing the lateromedial extent of the putamen at the level of the anterior commissure into eight segments and expressing the area of damage as the number of segments (0 to 8) involved.
A total measure for putaminal damage was obtained by multiplying the severity of damage (0 to 3) by area (0 to 8) to give a total putaminal score (range 0 to 24). Nigral and putaminal severity counts were combined as a striatonigral degeneration score (range 0 to 6), and severity counts in inferior olives, pontine nuclei, and cerebellar Purkinje cells as an olivopontocerebellar atrophy score (range 0 to 9). 
Results

CLINICAL FEATURES
There were 19 men and 16 women (ratio 1 2:1). Median age at disease onset was 55 (range 33 3-75 8) years. Death was at 62-8 (range 39-3-81 3) years, and median survival was 7-3 (range 2-1-15) years. There were no significant differences in any of these variables by sex. Thirty (86%) of the patients were considered to have multiple system atrophy of the striatonigral degeneration type, and five (14%) multiple system atrophy of the olivopontocerebellar atrophy type (table 1) .
The proportion of cases with some evidence of abnormalities in four major systems were as follows: autonomic 97 (95% confidence interval (95% CI) 85-100)%, parkinsonian 100 (95% CI 90-100)%, cerebellar 34 (95% CI 19-52)%, and pyramidal 54 (95% CI 36&7-71-2)%. Figure 1 shows the pattern of involvement of these four systems. The most frequent combination of clinical features was autonomic involvement with parkinsonism. Of the 35 cases, 22 (63%) had involvement of three or more systems; the remainder only showed clinical features of parkinsonism with (n = 12) or without (n = 1) autonomic involvement. Table 2 provides more detail on the presence of specific clinical features. Akinesia and rigidity were present in all patients and were usually asymmetric throughout the disease course. Tremor at rest was seen in a third of patients; however, a classical pill rolling rest tremor had been documented in only 11 %. All but one patient had autonomic failure according to our definition. Although symptomatic postural hypotension was noted in 71 % of the patients this was rarely severe, with recurrent (> 3) syncopal attacks occurring in only 20%. Urinary urge incontinence occurred in half of the patients, but faecal incontinence in one patient only. Urinary retention was less common, affecting a third of the patients. Persistent erectile dysfunction was reported by almost two thirds of men; there was no mention of potency in the remaining third.
Cerebellar gait ataxia and limb ataxia were seen in about 30% of the patients, and pyramidal signs were detected in 54%. Table 3 shows the prevalence of additional features. Reduced downgaze was noted in three (9%) patients; however, this deficit was only mild, and none of the cases had a prominent supranuclear downgaze palsy. Dysarthrophonia affected all but four patients and was commonly atypical with elements of straining, quivering, slurring, or scanning as well as the usual hypophonia and monotony of parkinsonism. Recorded sensory symptoms were uncommon (seven cases) and sensory loss even rarer (three cases).
When comparing sex distribution, age of onset, age at death, duration of disease, and response to levodopa for clinical subgroups, cases with cerebellar features (34%) were more likely to be men (p = 0.001), have a younger age of onset (p = 0.0005), and younger age of death (p = 0 003), but survival was little different from the other subgroups. Cases with severe autonomic involvement (37%) were also more likely to have a younger age of onset (p = 0 02) and of death (p = 0-05) and tended to have a poor response to levodopa although this failed to reach statistical significance (p = 0 06).
Levodopa was given to all but two patients. The initial clinical response for the whole sample was excellent (4) in 13%, good (3) in 25%, and poor (1-2) in 62%. The best recorded levodopa response was excellent (4) in 13%, good (3) in 32%, and poor (1-2) in 55%. The last recorded response in the notes, however, showed only 7% with a good response and 93% with a poor response. Motor response fluctuations were recorded in 60% of treated patients. Dyskinesiae developed in 52% of patients, involving facial musculature in 59% (12% unilateral) and limbs in 53% of them. Psychiatric side effects occurred in 15% (confusion in 9%, hallucinations and nightmares in 6% each). Figure 2 shows the disease progressionnamely, the median number of years to reach different Hoehn 
PATHOLOGY
Cell loss in the substantia nigra was identified in all but one case, which showed postmortem artefact (table 4) , and was severe in 79% (27/34) of them. The locus ceruleus was, with few exceptions, equally severely depleted.
Putaminal cell loss and gliosis were pronounced in 20 (61 %) and moderate or mild in 11 cases (33%). In two cases there was no putaminal cell loss and in two others infarction made interpretation of the extent of degenerative change difficult. Nevertheless, in all four cases both substantia nigra and locus ceruleus showed cell loss and gliosis without Lewy bodies. The pathological diagnosis of multiple system atrophy in the cases without putaminal cell loss would not have been possible but for the demonstration of glial cytoplasmic intrusions.z2
The caudate nucleus was much less severely affected: only two (6%) cases had severe cell loss and gliosis (usually diffuse) and 21 (66%) cases had mild or moderate gliosis, often in a focal dorsolateral distribution. There were no changes in nine (28%) cases. The external pallidum was invariably involved with gliosis except for the two cases without putaminal cell loss.
Degenerative changes in the olivopontocerebellar system were seen in 29 of 34 (88%) cases studied. Assessment was not possible in one case due to postmortem artefact. Pronounced Purkinje cell depletion was seen in the cerebellar cortex of 12 The estimated degree of olivopontocerebellar atrophy was unrelated to levodopa responsiveness. The presence of fluctuations and dyskinesiae was more often associated with severe striatonigral (striatonigral degeneration score 6) or putaminal (putamen score > 18) degeneration.
Cerebellar signs had been noted in life in only nine of the 26 (35%) cases that showed cerebellar Purkinje cell loss at postmortem. In 12 cases this Purkinje cell loss predominated in the vermis. Although all of them were noted to have postural instability in life, only three of them had definite evidence of gait ataxia.
We also examined the association between pathological damage and clinical features and subgroups. All the cases had parkinsonism and all showed pronounced damage to the nigra, and cases with cerebellar features or classified as olivopontocerebellar atrophy type had greater damage in the olivopontine area. Perhaps surprisingly, early loss of balance correlated significantly with putaminal damage but not with the olivopontocerebellar atrophy pathological score.
Discussion
The nosology of multiple system atrophy is complex, and related to the relative predominance of parkinsonism (striatonigral degeneration)," cerebellar signs (olivopontocerebellar atrophy), 14 or autonomic failure. Shy and Drager'4 reported two patients; pathology, which showed the classic changes of multiple system atrophy (both striatonigral degeneration and olivopontocerebellar atrophy), was obtained in one of them. Over subsequent years, the term Shy-Drager syndrome' has been used for cases of multiple system atrophy, and also misused to describe cases of Lewy body parkinsonism associated with severe autonomic failure. As virtually all patients with multiple system atrophy have some degree of clinical autonomic dysfunction (usually mild cardiovascular and more severe bladder involvement), we believe that it is most useful to divide them, according to their motor disorder, into parkinsonism predominant (striatonigral degeneration) or cerebellar predominant (olivopontocerebellar atrophy).
This study confirms and extends our knowledge about multiple system atrophy in a number of areas. It is a rapidly progressive disease, with a median survival of only five to six years from first symptom in over 200 cases of pathologically established multiple system atrophy recorded in the literature.8 In this series we found a longer median survival, of 7-3 (range 2 1 to 15) years, a discrepancy that might be due to the relative lack of clinical data in many of the published case reports. Moreover, in a follow up study of 100 patients with clinically probable multiple system atrophy we found a still longer median survival of 9 5 years.'6 The total disease duration from first symptom to death for our five patients with predominant olivopontocerebellar atrophy was similar to that for the 30 patients with predominant striatonigral degeneration, and the response of their (by definition mild or moderate) parkinsonism to levodopa was uniformly disappointing.
The finding of parkinsonism in 100% of our cases comes as little surprise given that the source of our material was a parkinsonian brain bank, but parkinsonism was also reported in 89% of pathologically established multiple system atrophy cases in the literature. Almost all patients with multiple system atrophy in our series had developed clinical signs of multisystem involvement by the time of death. Apart from one (2.9%) case with isolated parkinsonism, there was no case with autonomic failure, cerebellar, or pyramidal signs persisting in isolation throughout the course of disease. Among pathologically established cases of multiple system atrophy in the literature 90% had accrued in life features in two or more of these four clinical domains and only 10% apparently had parkinsonism in isolation at the time of death.
A good or excellent initial motor response to levodopa was seen in a third of this series of patients with multiple system atrophy. This was sustained until death, however, in only 7% of them. Thus although encountered in only a few patients, a positive and sustained levodopa response, even until death in some cases, can occur in multiple system atrophy. In this series there was a trend for the last, but not best, recorded levodopa response to be inversely associated with the degree of putaminal damage, consistent with previous more detailed morphometric data in a subgroup of cases.6 This finding might suggest that the severity of the nigral lesion precedes that of the striatal one. Further evidence for initial and more severe nigral cell loss is derived from two cases in our series with "minimal change" multiple system atrophy in which severe neuronal cell loss in substantia nigra was associated with preserved putaminal neurons12; however, typical glial cytoplasmic inclusions were found throughout the striatum and many other sites, indicating extranigral subcellular pathology. One of these two patients had a good, and one a negligible, response to levodopa. The substrate of levodopa unresponsiveness in multiple system atrophy is uncertain. Although loss of striatal dopamine receptors plays a part, much of the levodopa resistance in multiple system atrophy, and its heterogeneity between patients, is probably due to the variable degeneration of additional cell populations within the basal ganglia, involving other neurotransmitter systems. 8 us. Even retrospectively it was impossible in 10 of these cases to make a diagnosis of multiple system atrophy on the basis of the information recorded in their notes. The other two patients had developed pyramidal signs before death but remained diagnosed as Parkinson's disease. Although the presence of abnormal signs may suggest a diagnosis of multiple system atrophy, in many cases it may be the suspicion of multiple system atrophy that leads to the discovery of abnormal signs. Therefore a higher index of suspicion and regular follow up neurological examinations in all patients with parkinsonism may lead to more accurate diagnosis. Most cases of multiple system atrophy seem to start younger than is usual for Parkinson's disease, and it is of interest that the mean age of onset in the persistently misdiagnosed subgroup was significantly older than in the correctly diagnosed group. Even among those patients in whom an initial diagnosis of Parkinson's disease was subsequently changed to one of multiple system atrophy, this took an average of 4-4 years, indicating the difficulty of accurately diagnosing multiple system atrophy within the first five years. '7 Our pathological study showed that both substantia nigra and putamen were severely depleted in most cases. In a few cases severe nigral atrophy was associated with mild or moderate putaminal degeneration and in two cases definite cell loss was restricted to substantia nigra and locus ceruleus only.'2 The severity of pathological striatonigral degeneration did not correlate with age of onset and duration of disease, but did correlate with severity of disease at death.
Although 88% of our cases with available postmortem material had some evidence of olivopontocerebellar atrophy in addition to nigrostriatal cell loss, only 34% of them had definite cerebellar signs in life. Definite gait ataxia was only recorded in three of 12 cases with severe cerebellar (vermis) involvement, but impairment of postural reflexes with or without falls was present in all. The appreciation of a possible cerebellar component contributing to the disturbance of gait and postural control in multiple system atrophy is hampered by the presence of severe parkinsonism or symptomatic postural hypotension in many patients. The low number of cases with definite gait ataxia is therefore almost certainly an underestimate.
The association of olivopontocerebellar atrophy with striatonigral degeneration in such a large proportion of cases confirms the need for the term multiple system atrophy.I In our series, all cases with adequately fixed brains contained oligodendroglial inclusions that have been reported by a number of groups in the brains of patients with multiple system atrophy of various clinical subtypes, and are rarely if ever found in other sporadic or hereditary neurodegenerative diseases including hereditary olivopontocerebellar atrophy. As in previous reports, in our series these inclusions were found not only in the olivopontocerebellar and striatonigral systems, but also in a number of areas not previously considered to be affected in this disease including the cerebral cortex, external capsule, and brainstem reticular formation.9 19 22 The presence of these inclusions may account for more widespread alterations in cerebral function, such as the frontal lobe deficits documented in patients with multiple system atrophy.23 2 Furthermore, they constitute cytological grounds for considering sporadic striatonigral degeneration, Shy-Drager syndrome, and olivopontocerebellar atrophy together as multiple system atrophy, for differentiating them from hereditary olivopontocerebellar atrophy, and for defining multiple system atrophy as a specific entity that is only one among many different multisystem degenerations.26 GKW 
